MedPath
HSA Approval

INFANRIX HEXA VACCINE

SIN12288P

INFANRIX HEXA VACCINE

INFANRIX HEXA VACCINE

May 7, 2003

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Regulatory Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

Formulation Information

INJECTION

**Dosage and Administration** **Posology** The primary vaccination schedule consists of three doses (of 0.5 ml) which should be administered according to official recommendations (see _Pharmacodynamics_ for schedules evaluated in clinical trials – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Infanrix hexa can be considered for the booster if the antigen composition is in accordance with the official recommendations. ![Infanrix Hexa Vaccine Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/c674e40e028906934d1902a1666087e8.png) The vaccine may be used to complete a vaccination course initiated with Infanrix-IPV+Hib vaccine. During the development of the vaccine, the following primary vaccination schedules which are compatible with a policy of administering hepatitis B vaccine at birth were studied in full-term infants: at 2, 3, 4 months of age; at 2, 4, 6 months of age; at 1.5, 3, 5 months of age and at 6, 10, 14 weeks of age. Additionally, in a study in full-term infants undertaken in Singapore, Infanrix hexa was given as part of a 3, 4, 5 month schedule with Infanrix-IPV+Hib. The Infanrix-IPV+Hib was administered at months 3 and 4 and Infanrix hexa given at month 5. As part of this study, monovalent Hepatitis B vaccine was given at 0 and 1 month in accord with Singapore’s Hepatitis B immunisation policy. Immunogenicity data for preterm infants was solely obtained in trials that studied 2-4-6 months schedule for primary vaccination. Safety data for preterm infants was also obtained in study Rota-54 that included a greater variety of schedules, i.e. in France (2-3-4 months), Poland (2-3/4-5 months), Spain and Portugal (2-4-6 months). The Expanded Program on Immunisation schedule (at 6, 10, 14 weeks of age) may only be used if a dose of hepatitis B vaccine has been given at birth. Where a dose of hepatitis B vaccine is given at birth, Infanrix hexa can be used as a replacement for supplementary doses of hepatitis B vaccine from the age of 6 weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used. Locally established immunoprophylactic measures against hepatitis B should be maintained. **Method of administration** Infanrix hexa is for deep intramuscular injection.

INTRAMUSCULAR

Medical Information

**Indications** Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and _Haemophilus influenzae_ type b. The use of Infanrix hexa should be in accordance with official recommendations.

**Contraindications** Hypersensitivity to the active substances or to any of the excipients or residues such as formaldehyde, neomycin and polymyxin (see _Qualitative and quantitative composition_ and _List of Excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B, polio or Hib vaccines. Infanrix hexa is contraindicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria-tetanus, hepatitis B, inactivated polio and Hib vaccines.

J07CA09

diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B

Manufacturer Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE BIOLOGICALS SA

GlaxoSmithKline Biologicals

GSK Biologicals SA

Active Ingredients

HIB PURIFIED CAPSULAR POLYSACCHARIDE BOUND TO TETANUS TOXOID

10 mcg/0.5 ml

HEPATITIS B SURFACE ANTIGEN (PURIFIED)

10 mcg/0.5 ml

DIPHTHERIA TOXOID

min 30 iu/0.5 ml

PERTACTIN (69 kDa OMP)

8 mcg/0.5 ml

POLIOVIRUS TYPE 1 (INACTIVATED)

40 du/0.5 ml

FILAMENTOUS HAEMAGGLUTININ

25 mcg/0.5 ml

PERTUSSIS TOXOID

25 mcg/0.5 ml

POLIOVIRUS TYPE 3 (INACTIVATED)

32 du/0.5 ml

POLIOVIRUS TYPE 2 (INACTIVATED)

8 du/0.5 ml

Documents

Package Inserts

Infanrix Hexa PI.pdf

Approved: May 31, 2023

Download
© Copyright 2025. All Rights Reserved by MedPath